Cairo, Egypt

Combined Drug Radiation Treatment

From chemo-radiotherapy to immunotherapy and radiation, this course will increase your confidence in combined drug – radiation therapy: right patient, right drug, right  radiotherapy, right dose, right time.

The course is aimed at radiation oncologists and medical oncologists involved in the multidisciplinary treatment of cancer.

COURSE DIRECTOR

Barbara Jereczek-Fossa, Radiation Oncologist and Clinical Oncologist, European Institute of Oncology and University of Milan, Milan (IT)

TEACHERS

• Giuseppe Curigliano, Medical Oncologist, European Institute of Oncology, Milan (IT)

• Mario Levis, Radiation Oncologist, University of Turin, Turin (IT)

• Jesper Grau Eriksen, Clinical Oncologist, Aarhus University Hospital, Aarhus (DK)

• Martin Pruschy, Biologist, University Hospital Zürich, Zürich (CH)

• Li Tee Tan, Clinical Oncologist, Cambridge University Hospital, NHS Trust, Cambridge (UK)

• Rob Glynne-Jones, Clincial Oncologist, Mount Vernon Cancer Centre, Northwood (UK)

 

Course rationale

Effective cancer treatment necessitates both high efficacy of local treatment and combatting subclinical systemic disease.  Consequently, cancer therapy today involves various combinations of local and systemic treatment modalities. Of those, combining drugs and radiation has been attracting particular attention both in terms of its biological rationale and its potential of increasing the therapeutic outcome. This course aims at updating participants about established and emerging knowledge in this field. It will provide the key messages that biological and clinical research is currently bringing to the oncology community.

 

This course aims to:

• Update participants about the biological effects of combining drugs and radiation in normal and tumour tissue

• Present evidence-based clinical applications of combined modality treatment using drugs and radiation in major human malignancies

• Stimulate case-based discussion on the interdisciplinary treatment of cancer

• Present future perspectives for combining drugs and radiation

Learning Outcomes

By the end of this course participants should be able to:

  • Describe the rationale and mechanisms of the action of combined drug radiation treatment in cancer
  • Discuss the evidence for combined drug radiation treatment in different tumour sites
  • Select patients for combined drug radiation treatment
  • Decide on the optimum treatment strategy, sequencing and duration, for different patients
  • Decide on the optimum strategy including new drugs (immunotherapy etc.)

Course Content

General lectures

  • Biologic basis for combining drugs with radiation
  • Combining drugs with radiation: quantifying the therapeutic gain
  • Combining new drugs with radiotherapy
  • Radiation and non-cytotoxic drugs
  • Hypoxic cell radiosensitisers
  • Alteration of radiotherapy fractionation and concurrent chemotherapy
  • Designing clinical trials for combined modality treatments.
  • Site specific lectures including practical case discussions
  • Head and neck cancer
  • Non small cell lung cancer
  • Small cell lung cancer
  • Breast cancer
  • Prostate cancer
  • Bladder cancer
  • Cervical cancer
  • Oesophageal cancer
  • Gastric cancer
  • Rectal cancer
  • Anal canal
  • Pancreas
  • Brain tumours
  • Lymphomas

Prerequisites

Before commencing this course participants should:

  • Be confident with the basic mechanisms of radiotherapy and systemic treatment in oncology
  • Know the basic principles of management of solid tumours
  • Know different ways of delivering chemotherapy/systemic therapy in combination with radiotherapy

Teaching Methods

  • 20 hours of lectures
  • 5 hours of case discussions
  • Presentation and critical discussion of the available evidence, discussion of clinical cases

Methods of Assessment

In-class voting

 

Course Flyer

Programme

To follow

Accreditation

Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtained from the ESTRO office.

Venue

To follow

Registration can be done here.

Any questions can be directed to mpalmu@estro.org.